Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cellophil™ is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More
Your selection
Browse By
- Therapeutic target
- Anti-oxidant
- Bladder cancer
- Bone cancer
- Brain cancer
- Breast cancer
- Cancer (other)
- Cancer side effects
- Cervical cancer
- Colorectal cancer
- Head and neck cancer
- Kaposi's sarcoma
- Kidney cancer
- Leukemia
- Liver cancer
- Lung cancer
- Lymphoma
- Ovarian cancer
- Pancreatic cancer
- Polyps
- Prostate cancer
- Skin cancer
- Stomach/Esophageal
- Testicular cancer
- Transplant
- Treatments
- Tumor (other)
- Vaginal Cancer
- Womb cancer
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us